Tremilimumab in pleural or peritoneal malignant mesothelioma

• Research type

  Research Study

• Full title

  A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

• IRAS ID

  131970

• Contact name

  Christian Ottensmeier

• Contact email

  c.h.ottensmeier@soton.ac.uk

• Eudract number

  2012-003524-21

• Clinicaltrials.gov Identifier

  NCT01843374

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0384

• Date of REC Opinion

  30 Sep 2013

• REC opinion

  Further Information Favourable Opinion